{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:48:07Z","timestamp":1789012087835,"version":"build-2803163510"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32AI007517-20"],"award-info":[{"award-number":["5T32AI007517-20"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Rare cases of thrombosis and thrombocytopenia (thrombosis with thrombocytopenia syndrome [TTS]) have been associated with 2 coronavirus disease 2019 adenovirus vector vaccines: the ChAdOx1 nCoV-19 Vaxzevria vaccine (Oxford\/AstraZeneca) and the JNJ-7836735 Johnson &amp; Johnson vaccine (Janssen). It is unknown if TTS is a class-mediated effect of adenovirus-based vaccines or if it could worsen known hypercoagulable states. Since most cases of TTS happen in women of childbearing age, pregnancy is a crucial risk factor to assess. Understanding these risks is important for advising vaccine recipients and future adenovirus vector vaccine development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To explore the potential associations of adenovirus-based vaccine components with symptoms of TTS in the general clinical trial population and in pregnant women in clinical trials, we conducted a systematic review and meta-analysis of adenovirus-based vector vaccines to document cases of thrombocytopenia, coagulopathy, and or pregnancy from 1 January 1966 to 9 August 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found 167 articles from 159 studies of adenovirus vector\u2013based vaccines, 123 of which targeted infectious diseases. In the general population, 20 studies reported an event of thrombocytopenia and 20 studies indicated some coagulopathy. Among pregnant women, of the 28 studies that reported a total of 1731 pregnant women, thrombocytopenia or coagulopathy were not reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this systematic review and meta-analysis, there was no class-wide effect of adenovirus vector vaccines toward thrombocytopenia or coagulopathy events in the general population or in pregnant women.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac080","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T04:13:30Z","timestamp":1643343210000},"page":"1179-1186","source":"Crossref","is-referenced-by-count":11,"title":["Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-0084","authenticated-orcid":false,"given":"Lauren","family":"Pischel","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut , USA"},{"name":"Yale School of Public Health , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9406-1351","authenticated-orcid":false,"given":"Kavin M","family":"Patel","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-4427","authenticated-orcid":false,"given":"George","family":"Goshua","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medicine, Yale School of Medicine , New Haven, Connecticut , USA"},{"name":"Department of Health Policy and Management, Harvard T. H. Chan School of Public Health , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-3474","authenticated-orcid":false,"given":"Saad B","family":"Omer","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut , USA"},{"name":"Yale School of Public Health , New Haven, Connecticut , USA"},{"name":"Yale Institute of Global Health , New Haven, Connecticut , USA"},{"name":"Yale School of Nursing , Orange, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"2022093020410007400_CIT0001","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine\u2013induced immune thrombotic thrombocytopenia.","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0002","article-title":"Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia)","author":"Bussel"},{"key":"2022093020410007400_CIT0003","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0004","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0005","article-title":"ISTH interim guidance for the diagnosis and treatment on vaccine-induced immune thrombotic thrombocytopenia.","author":"International Society on Thrombosis and Haemostasis.","year":"2021"},{"key":"2022093020410007400_CIT0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/cclm-2021-1039","article-title":"Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT).","volume":"60","author":"Favaloro","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"2022093020410007400_CIT0007","article-title":"Interim case definition of thrombosis with thrombocytopenia syndrome (TTS)","author":"Task Force for Global Health."},{"key":"2022093020410007400_CIT0008","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0003-4975(03)01523-6","article-title":"Risk factors for mediastinitis after cardiac surgery.","volume":"77","author":"Abboud","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"2022093020410007400_CIT0009","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0010","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0011","doi-asserted-by":"crossref","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.","volume":"7","author":"Baker","year":"2021","journal-title":"Sci Adv"},{"key":"2022093020410007400_CIT0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"key":"2022093020410007400_CIT0013","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMra0707993","article-title":"Venous thromboembolic disease and pregnancy.","volume":"359","author":"Marik","year":"2008","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0014","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.21037\/cdt.2017.10.08","article-title":"Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management.","volume":"7","author":"Devis","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2022093020410007400_CIT0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques.","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum Gene Ther"},{"key":"2022093020410007400_CIT0016","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses.","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"key":"2022093020410007400_CIT0017","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"2022093020410007400_CIT0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial.","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2022093020410007400_CIT0019","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12250-014-3507-x","article-title":"Viral respiratory infections among Hajj pilgrims in 2013.","volume":"29","author":"Barasheed","year":"2014","journal-title":"Virol Sin"},{"key":"2022093020410007400_CIT0020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/sj.mt.6300078","article-title":"A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.","volume":"15","author":"Tatsis","year":"2007","journal-title":"Mol Ther"},{"key":"2022093020410007400_CIT0021","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/21645515.2017.1264755","article-title":"Two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.","volume":"13","author":"Shukarev","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2022093020410007400_CIT0022","doi-asserted-by":"crossref","first-page":"1829829","DOI":"10.1080\/16549716.2020.1829829","article-title":"Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.","volume":"13","author":"Kitonsa","year":"2020","journal-title":"Glob Health Action"},{"key":"2022093020410007400_CIT0023","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1086\/650299","article-title":"A phase 1\/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV 172).","volume":"201","author":"Kibuuka","year":"2010","journal-title":"J Infect Dis"},{"key":"2022093020410007400_CIT0024","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2022093020410007400_CIT0025","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia.","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"2022093020410007400_CIT0026","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA.","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022093020410007400_CIT0028","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2022093020410007400_CIT0029","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia.","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0030","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4161\/hv.24941","article-title":"Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.","volume":"9","author":"Tamminga","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2022093020410007400_CIT0031","doi-asserted-by":"crossref","first-page":"286re","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022093020410007400_CIT0032","doi-asserted-by":"crossref","first-page":"e0166393","DOI":"10.1371\/journal.pone.0166393","article-title":"Safety and immunogenicity of a rAd35-EnvA prototype HIV-1 vaccine in combination with rAd5-EnvA in healthy adults (VRC 012).","volume":"11","author":"Crank","year":"2016","journal-title":"PLoS One"},{"key":"2022093020410007400_CIT0033","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2017.1342021","article-title":"Open-label phase I clinical trial of Ad5-EBOV in Africans in China.","volume":"13","author":"Wu","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2022093020410007400_CIT0034","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine.","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study.","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022093020410007400_CIT0036","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination.","volume":"384","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"key":"2022093020410007400_CIT0037","volume-title":"FDA review of efficacy and safety of the Janssen COVID-19 vaccine emergency use authorization request","author":"Zhang","year":"2021"},{"key":"2022093020410007400_CIT0038","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2022093020410007400_CIT0039","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"2022093020410007400_CIT0040","volume-title":"Briefing document. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting","author":"US Food and Drug Administration.","year":"2021"},{"key":"2022093020410007400_CIT0041","volume-title":"Vaccines and Related Biological Products Advisory Committee, February 26, 2021 meeting briefing document\u2014sponsor","author":"US Food and Drug Administration.","year":"2021"},{"key":"2022093020410007400_CIT0042","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(20)30016-5","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2022093020410007400_CIT0043","doi-asserted-by":"crossref","first-page":"e24517","DOI":"10.1371\/journal.pone.0024517","article-title":"Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.","volume":"6","author":"Koblin","year":"2011","journal-title":"PLoS One"},{"key":"2022093020410007400_CIT0044","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/10430349950018229","article-title":"In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.","volume":"10","author":"Herman","year":"1999","journal-title":"Hum Gene Ther"},{"key":"2022093020410007400_CIT0045","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archoto.2009.122","article-title":"A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group.","volume":"135","author":"Yoo","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2022093020410007400_CIT0046","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1006\/mthe.2001.0444","article-title":"Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial.","volume":"4","author":"Sung","year":"2001","journal-title":"Mol Ther"},{"key":"2022093020410007400_CIT0047","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/gt.2008.179","article-title":"A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.","volume":"16","author":"Li","year":"2009","journal-title":"Gene Ther"},{"key":"2022093020410007400_CIT0048","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.","volume":"13","author":"Raper","year":"2002","journal-title":"Hum Gene Ther"},{"key":"2022093020410007400_CIT0049","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.urology.2005.04.041","article-title":"Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants.","volume":"66","author":"Malaeb","year":"2005","journal-title":"Urology"},{"key":"2022093020410007400_CIT0050","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Ther"},{"key":"2022093020410007400_CIT0051","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2003.09.114","article-title":"Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.","volume":"21","author":"Hamid","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022093020410007400_CIT0052","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.gt.3301398","article-title":"Safety and feasibility of injection with an E1B-55\u00a0kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.","volume":"8","author":"Mulvihill","year":"2001","journal-title":"Gene Ther"},{"key":"2022093020410007400_CIT0053","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1479-5876-11-62","article-title":"Phase 1 studies of the safety and immunogenicity of electroporated HER2\/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.","volume":"11","author":"Diaz","year":"2013","journal-title":"J Transl Med"},{"key":"2022093020410007400_CIT0054","doi-asserted-by":"crossref","first-page":"e000928","DOI":"10.1136\/jitc-2020-000928","article-title":"Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.","volume":"8","author":"Cappuccini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2022093020410007400_CIT0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022093020410007400_CIT0056","article-title":"COVID-19 vaccines while pregnant or breastfeeding","author":"Centers for Disease Control and Prevention."},{"key":"2022093020410007400_CIT0057","article-title":"Updates on thrombosis with thrombocytopenia syndrome (TTS)","author":"See"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac080\/42688534\/ciac080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/7\/1179\/46227357\/ciac080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/7\/1179\/46227357\/ciac080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T20:47:06Z","timestamp":1664570826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/7\/1179\/6520532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,2,2]]},"published-print":{"date-parts":[[2022,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac080","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,2,2]]}}}